BSTE 2022
9th Belgian Symposium on Tissue Engineering

December 2 & 3, 2022


Confirmed Speakers

Marcy Zenobi-Wong

Marcy Zenobi-Wong is a tenured Full Professor of Tissue Engineering and Biofabrication and Director of the Institute for Biomechanics at ETH Zürich in Switzerland.  She is a Mechanical Engineer by training, and received her Bachelor degree from MIT and Master/PhD from Stanford University.   She leads a multidisciplinary team with strong focus on biofabrication technologies including bioprinting, two-photon polymerization, and casting, and on the development of advanced biomaterials for tissue regeneration. She is the author of over 100 peer-reviewed publications (cited over 5000 times) and co-inventor on several licensed patents. She is an honorary member of the Swiss Society for Biomaterials and Regenerative Medicine (SSB+RM) and General Secretary for the International Society of Biofabrication (ISBF).  She serves on the editorial board for Biofabrication and Advanced Healthcare Materials.  In 2019 she was elected as Fellow to the European Alliance for Medical & Biological Engineering and Science (EAMBES).

Laura Koivusalo

Dr Laura Koivusalo is an expert in biomaterials and tissue engineering. She conducted her PhD in Tampere University under Professor Heli Skottman, where she developed hydrogel-based biomaterials for delivering human stem cells to the corneal surface. While finalizing her PhD, she started to lead a commercialization project from Skottman Lab, which led to the establishment of a spin-off company StemSight in April 2021. StemSight’s mission is to use human induced pluripotent stem (iPS) cells to manufacture off-the-shelf therapies to cure corneal blindness. In leading the company as a CEO, Laura has won several pitching competitions and been awarded as the Outstanding Young Person of the Year 2021 in medical innovation by JCI Finland.

Jaap den Toonder

Jaap den Toonder is full professor and chair of the Microsystems section at Eindhoven University of Technology (TU/e). He received his master’s degree in applied mathematics in 1991 (cum laude), and his PhD degree in mechanical engineering in 1996 (cum laude), both from Delft University of Technology. In 1995, he joined Philips Research Laboratories in Eindhoven, where he worked on a wide variety of applications. In 2008, he became chief technologist, leading the R&D programs on (micro-)fluidics and materials science and engineering. Next to his main job at Philips, he was a part-time professor of Microfluidics Technology at Eindhoven University of Technology between 2004 and 2013.
Jaap den Toonder’s research focuses on the investigation and development of novel microsystems design approaches, out-of-cleanroom fabrication technologies, and interactive polymer materials. The application focus is on microfluidic chips, organ-on-chip, biomedical microdevices, and soft microrobotics. The section’s research approaches are often biologically inspired, translating principles from nature into technological innovations.
Jaap den Toonder has (co-)authored over 130 scientific papers, as well as over 45 patents, and he has given more than 50 invited lectures at international conferences. Jaap den Toonder has founded and directs the Microfab/lab: a state‐of‐the‐art facility at TU/e that encompasses a unique set of many techniques needed to create and analyse microfluidic devices and microsystems including biological materials. He teaches courses on microfabrication methods, microfluidics, and heat and flow in microsystems, in which hands-on learning is a key element.  Jaap den Toonder is recipient of an ERC Advanced Grant in 2019. Jaap den Toonder has been one of the frontrunners of organ-on-chip, being co-organizer of one of the first international workshops on organ-on-chip, held in 2012 at the Lorentz Center, the Netherlands, which kicked off the organ-on-chip development in the Netherlands and Europe, resulting among other things in the establishment of the Dutch organ-on-chip consortium hDMT.

Christophe Deben

In 2016, dr. Deben successfully defended his PhD dissertation on targeting the p53 patway in non-small cell lung cancer at the Univeristy of Antwerp in the Center for Oncological Research (CORE). In 2017, he started in his current position as a post-doctoral researcher at CORE focussing on targeting redox biology for the treatment of cancer and the implementation of patient-derived organoids (PDOs). In particular, he focused on the development of live-cell imaging-based screening assay for PDOs and co-developed the Orbits AI-based image analysis software for label free monitoring of PDOs together with InViLab (UAntwerp). In 2021, he became the head of the Tumoroid Screening lab (TUSC, UAntwerp) which processes patient samples into organoids and provides advanced PDO screening services based on live-cell imaging.

Shulamit Levenberg

Professor Shulamit Levenberg is the head of the Stem cell and Tissue engineering lab at the Technion Faculty of Biomedical Engineering and the director of the Technion Center for 3D Bioprinting. She earned her PhD at the Weizmann Institute of Science and pursued her post-doctoral research at MIT in the lab of Professor Robert Langer. She spent a sabbatical year as a visiting professor at the Wyss Institute for Biology Inspired Engineering at Harvard University and a summer sabbatical at the University of Western Australia as a winner of the Raine Visiting Professor Award. Prof. Levenberg research involve in vitro vascularization of engineered tissues where, upon implantation, the engineered vessels anastomose with the host vasculature, improving survival and perfusion of engineered grafts. Prof. Levenberg was the first to engineer vascularized tissue flaps, offering novel reconstruction techniques using engineered tissue constructs. Her pioneering work demonstrated the effect of scaffold stiffness and tensile forces on early differentiation and organization of stem cells in 3D constructs, and on alignment of vessel networks in engineered tissues. She recently developed unique stem-cell engineered tissue constructs that induce the regeneration and repair of injured spinal cords and a genetically engineered muscle tissue for treatment of type 2 diabetes. Prof Levenberg was named by Scientific American as a “Research Leader” in tissue engineering and received numerous prizes. The most recent ones include the Rappaport Prize for Excellence in Biomedical Sciences, the Michael Bruno Memorial Award, the Katz prize and a Medal of Distinction from the Peres Center for Peace and Innovation She is founder and CSO of three start-up companies in the areas of cultured meat, spinal cord regeneration and nanoliter diagnostic arrays.  Prof Levenberg is the former President of the Israel Stem Cell Society and the former Dean of the Technion Faculty of Biomedical Engineering.

Seppe Terryn

Dr. ir. Seppe Terryn received his PhD in 2019 at the Vrije Universiteit Brussel, in which he combined smart materials and robotics and developed a new multidisciplinary field “self-healing soft robots”. He is currently working as Postdoctoral researcher with a personal grant of the FWO and is co-managing three European projects; FET Open SHERO on self-healing soft robots, the EU Marie Curie ITN SMART on smart materials for robots, the EIC Transition on self-healing materials for sustainable products and an FWO SBO AMSER on additive manufacturing of self-healing robots. In these projects, he is currently guiding a team of 10 PhD students working on increasing the TRL-level of self-healing soft robots and soft electronics towards industrial applications, while performing fundamental research on self-healing polymers/composites, (additive) manufacturing, self-healing sensors and actuators. 

Elena Kozlova

Prof. dr.  Elena N. Kozlova is leading the Regenerative Neurobiology lab in the Department of Neuroscience at Uppsala University. Before that, she was a Postdoctoral researcher at the Karolinska institutet (Sweden) and National Institute for Medical Research (UK). Prof. Kozlova has published 58 original publications and 8 review articles and 2 book chapters. She was a coordinator of EU-sponsored project within EuroNanoMed II, partner in EU-sponsored project within Joint Program in Neurodegenerative Disease (JPND), member of management committee COST Action Biomaterials and advanced physical techniques for regenerative cardiology and neurology.

Prof. Kozlova’s research is focused on developing novel treatment strategies for spinal cord injury and disease, specifically neurodegenerative disorders, as well as in exploring the impact of extreme gravity alterations on the properties of neural stem cells. The research includes human induced pluripotent stem cell-derived neural stem cells, as well as the application of mesoporous nanoparticles for therapeutic purposes.

Olivier Guillaume

I graduated my PhD in 2011 in the field of polymeric biomaterials used for soft tissue repair, with a focus on antimicrobial surfaces. The following years, I spent several post-doctoral trainings in the field of tissue engineering and regenerative medicine, applying new biomaterials combined with cells, for bone, cartilage, IVD and muscle repair (at the Trinity College Dublin-IR and AO Davos-CH). Since 2018, I am working as Univ. Assist. in the group of Prof Ovsianikov Aleksandr: “3D Printing and Biofabrication Group” from the Institute of Materials Science and Technology of the Technische Universität Wien-Austria (Additive Manufacturing Technologies : AMT ( We focus our effort in adapting multi-photon lithography for biomedical and TERM purposes. Over the last years, we have shown that MPL offers unrivalled opportunities to build scaffolds and to bioprint hydrogels with highly intricated but easily controllable features, or to be used for organ-on-a-chip technologies. One particular interest is to assess a new approach for TERM application, consisting in merging together the two commonly used strategies, i.e. the scaffold-free and scaffold-based. This new approach, called the “third tissue engineering strategy”, requires the fabrication of multiple micro-size scaffolds which allow the formation of single spheroids in their core. The cellularized units can then be used as injectable building blocks and can self-assemble to form larger-size and stable tissues, features hardly achievable using the previously two well-known approaches. We are currently assessing how those stem cell-loaded microscaffolds can be used to regenerate musculoskeletal defects, with a focus on bone and cartilage tissues.